AzTrials
AzTrials

PsoriasisPhase 1NCT04843631

Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults

A Phase 1 study testing BFI-751, EU-STELARA® and US-STELARA® in people with Psoriasis, run by BioFactura Australia Pty Ltd. at 3 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

BFI-751 is being developed by BioFactura Australia Pty Ltd as a biosimilar drug to Stelara® (EU licenced and US licenced) (ustekinumab) is a prescription biologic medicine used to treat people with Crohn's disease, Ulcerative Colitis, plaque psoriasis and psoriatic arthritis. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
Psoriasis
What is being tested?
BFI-751, EU-STELARA® and US-STELARA®
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
216 participants
Where
3 sitesin 2 countries
Study dates
1 Apr 2021to 8 Dec 2021
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy volunteers will be included in the study if they meet all of the following criteria at screening, and after check-in on Day -1, prior to dose administration:
  • Must have given written informed consent before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
  • Adult male and female volunteers, 18 to 50 years of age (inclusive).
  • Subjects who smoke no more than 2 cigarettes or equivalent per week can be included in the study but must be willing to abstain from smoking 7 days prior to admission and during the confinement period. Subjects must have a negative test for cotinine prior to check-in on Day -1.
  • Body mass index (calculated) within the range of 18 to 32 kg/m2 inclusive.
  • Body weight ≥ 50 kg and ≤ 100 kg inclusive.
Show all 20Show fewer
  • Medically healthy without clinically significant abnormalities, including:
  • Physical examination without any clinically significant findings, in the opinion of the Investigator.
  • Systolic blood pressure (BP) in the range of 90 to 145 mm Hg (inclusive) and diastolic BP in the range of 50 to 90 mm Hg (inclusive) after at least 5 minutes in the supine position.
  • Heart rate (HR) in the range of 40 to 100 beats/min (inclusive) after at least 5 minutes rest in a supine position.
  • Normal body temperature 35.5 to 37.7°C (inclusive).
  • Triplicate 12-lead electrocardiogram (ECG), taken after the volunteer has been supine for at least 5 minutes, with a QT interval corrected using the Fridericia method (QTcF) ≤ 450 msec for males and ≤ 470 msec for females and no clinically significant abnormalities, in the opinion of the Investigator.
  • No clinically significant findings in serum chemistry, haematology, coagulation and urinalysis examinations, in the opinion of the Investigator.
  • Assessments may be repeated once, if abnormal values were recorded in the first instance, at the discretion of the Investigator.
  • Female volunteers must:
  • Be of non-child-bearing potential i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the Screening visit) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a follicle-stimulating hormone level indicative of postmenopausal status per local laboratory definition), OR
  • If of childbearing potential, must agree not to donate ova, not to attempt to become pregnant, and, if engaging in sexual intercourse with a male partner must agree to use an acceptable method of contraception for from signing the consent form until at least 15 weeks after the last dose of study drug.
  • Male volunteers, must agree not to donate sperm and if engaging in sexual intercourse with a female partner who could become pregnant, must agree to use an acceptable form of contraception from signing the consent form until at least 15 weeks after the last dose of study drug.
  • Have suitable venous access for blood sampling.
  • Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.

Who cannot join

  • Healthy volunteers will be excluded from the study if there is evidence of any of the following at screening or after check-in on Day -1, prior to dose administration:
  • 1. Prior exposure to STELARA® (Ustekinumab).
  • Have a history of hypersensitivity or allergic reactions (either spontaneous or following drug administration) to any of the active or formulation ingredients of the study treatments components.
  • Have a history of or presence of disease determined by the PI to be clinically significant including:
  • gastrointestinal (including diverticulitis, stomach ulcers, inflammatory intestinal disease, gastrointestinal perforations/fistulae/intra-abdominal abscess).
  • any other internal, non-gastrointestinal fistulae that is at an increased risk of bleeding.
Show all 42Show fewer
  • haematological (including pancytopenia, aplastic anaemia or blood dyscrasia).
  • renal, hepatic, pulmonary, neurologic, psychiatric, metabolic (including known diabetes mellitus), or
  • allergic disease excluding mild asymptomatic seasonal allergies.
  • Have a history of prolonged immunosuppressant therapy, or photochemotherapy treatment.
  • Presence or evidence of recent sunburn, scar tissue, tattoo (more than 25% of body area), open sore or branding that, in the opinion of the Investigator, would interfere with interpretation of skin adverse reactions.
  • Have a history of and/or current cardiac disease defined as one of the following:
  • History of congestive heart failure; angina pectoris requiring anti-anginal medication.
  • Evidence of transmural infarction on ECG.
  • History of sustained hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg) or hypertensive crisis or hypertension encephalopathy.
  • Clinically significant valvular heart disease, or severe arterial thromboembolic events.
  • Have a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus, human immunodeficiency virus (HIV) or history of active, latent or inadequately treated tuberculosis (TB) infection.
  • Positive serum pregnancy test for women of childbearing potential at the Screening visit or positive urine pregnancy test with confirmatory serum pregnancy test prior to dosing on Day 1.
  • Females who are breastfeeding.
  • Have a history of cancer including lymphoma, leukaemia and skin cancer (volunteers with a maximum of 1 surgically resected basal cell carcinoma or squamous cell carcinoma are permitted).
  • Have an illness within 30 days prior to screening, or prior to dosing, that is classed as clinically significant by the Investigator.
  • Prior exposure to any investigational monoclonal antibody within 12 months or 5 half-lives of the previous drug (if known), whichever is longer, prior to study drug administration.
  • Have participated in another clinical study of an investigational drug (excluding monoclonal antibody) within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to the administration of the study drug, or are currently participating in another clinical study of an investigational drug, or intending to participate in another clinical study of an investigational drug before completion of all scheduled evaluations in this clinical study.
  • Any clinically significant infection, in the opinion of the Investigator, ongoing at screening or admission to the clinical unit.
  • Have had major surgery within 30 days prior to screening or will have an operation between screening and the end of study visit, or have any unhealed wound, including wound dehiscence and wound healing complications requiring medical intervention.
  • Have received any vaccine(s) within 14 days prior to check in on Day -1, or is planning to receive any vaccine with 14 days following dose administration on Day 1.
  • Have received a Bacillus Calmette-Guerin (BCG) vaccination within 1 year prior to dose administration, or is planning to receive a BCG vaccination within 1 year following dose administration.
  • History of alcohol abuse (defined as more than 12 standard drinks per week or more than 4 standard drinks on > 3 days per week; where 1 standard drink is 10 g of pure alcohol and is equivalent to 285 mL beer [4.9% Alc./Vol], 100 mL wine [12% Alc./Vol], 30 mL spirit [40% Alc./Vol]) within 12 weeks prior to the screening visit.
  • Positive drug or alcohol test results. In the event the urinary drug test is positive, the test may be repeated once (at the discretion of the PI) to confirm eligibility.
  • Have donated > 100 mL blood within 4 weeks prior to the administration of the study drug.
  • Abnormal or irregular bowel movements, in the opinion of the Investigator.
  • Any history of non-traumatic haemorrhage (i.e. any haemorrhage requiring medical intervention) or any condition which may increase bleeding risk including clotting disorders, thrombocytopenia (platelet count < 150, 000 per μL) or an international normalised ratio higher than 1.5.
  • Impaired liver function as determined by a serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)> 1.5 x upper limit of normal (ULN) at screening or admission. Subjects with values between ULN and 1.5 x ULN may be included in the study if considered not clinically significant by the Investigator.
  • Use of any prescription or over-the-counter medication (including herbal products, diet aids, and hormone supplements) within 10 days or 5 half-lives of the medication (whichever is longer) prior to the first study drug administration, which, in the opinion of the Investigator, could affect the outcome of the study. The following exceptions apply:
  • Contraceptives for WOCBP are permitted.
  • Paracetamol (up to a maximum of 4 doses of 500 mg per day, and no more than 3g per week) is permitted.
  • Ibuprofen (up to a maximum of 4 doses of 200 mg per day) is permitted.
  • Consumption of any foods containing poppy seeds within 48 hours prior to screening and admission to the clinical centre.
  • Presence of proteinuria (other than trace amounts i.e., +, ++/+++).
  • Personal history of venous thromboembolic events or idiopathic venous thromboembolic events in a first degree relative.
  • Any person who is an employee of an Investigator or Sponsor, or an immediate relative of an Investigator.
  • Any other condition or prior therapy that in the opinion of the Investigator would make the volunteer unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.

Trial locations and contacts

3 sites in 2 countries.

3 sites in 2 countries

Australia2 sites

  • CMAX

    Adelaide, South Australia, 5000

  • Nucleus Network

    Brisbane, Queensland, 4029

Other trials in Australia

New Zealand1 site

  • NZCR

    Grafton, Auckland, 1010

Other trials in New Zealand

About this study

Official title: Bioequivalence Randomised, Double-blind, 3-parallel -Group Phase I Study of BFI-751 Compared With EU-STELARA® and US-STELARA® in Healthy Adult Volunteers

BFI-751 is being developed by BioFactura Australia Pty Ltd as a biosimilar drug to Stelara® (EU licenced and US licenced) (ustekinumab) is a prescription biologic medicine used to treat people with Crohn's disease, Ulcerative Colitis, plaque psoriasis and psoriatic arthritis. Stelara® is an immune suppressant that reduces the effects of inflammatory proteins within the body.

This is the first time BFI-751 will be given to humans. The primary purpose of this study is to compare the pharmacokinetics (the study of what the body does to the drug, referring to the movement of any drug going into, through, and out of the body) by checking to see if the blood levels of 751-BFI are comparable with US-Stelara® and EU-Stelara® following a single injection under the skin.

Read more

The secondary purposes of this study are:

  • to assess the safety of BFI-751,
  • study how well the healthy volunteers tolerate it and
  • to also assess the immune response to it in healthy volunteers.
Read the detailed description

This is a two centre, bioequivalence, randomized, double-blind, 3 parallel group Phase 1 study of BFI-751 compared with EU-Stelara ® and US-Stelara ® in healthy adult volunteers.

Within 28 days of screening, eligible participants will commence a confinement period on Day -1. The participants will receive a 45mg dose of either BFI-751, Stelara-US ® or Stelara-EU® in a blinded manner on Day 1 and will remain in the clinic until Day 2.

Participants will then return to the clinic as outpatients on Days 3, 5, 8, 11, 15, 22, 29, 36, 43,57, 71 and 85 for safety assessments.

A total of up to 228 eligible participants will be enrolled and randomised in a 1:1:1 ratio (BFI-751: EU-Stelara ® : US-Stelara ® ).

Conditions
Psoriasis
Being tested
BFI-751, EU-STELARA®, US-STELARA®
Medical subject headings
Psoriasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BFI-751Drug

    Also called Ustekinumab Biosimilar

    Single use vial, solution

  • EU-STELARA®Drug

    Also called STELARA® (ustekinumab)

    Pre-filled syringe, solution

  • US-STELARA®Drug

    Also called STELARA® (ustekinumab)

    Pre-filled syringe, solution

Study groups in NCT04843631
Study groupRoleWhat they receive
Arm A: BFI-751ExperimentalOn Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL BFI-751
Receives: Drug: BFI-751
Arm B: EU-STELARA®Active comparatorOn Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL EU- STELARA®
Receives: Drug: EU-STELARA®
Arm C: US-STELARA®.Active comparatorOn Day 1, participants will be randomised to receive a single SC dose of 45 mg/0.5mL US- STELARA®
Receives: Drug: US-STELARA®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bioequivalence- Cmax

    Compare Maximum observed concentration (Cmax) of BFI-751 with EU-Stelara and US-Stelara following a single 45 mg SC injection

    Measured: From Baseline to Day 85

  2. Bioequivalence-Tmax

    Compare Time to Cmax (Tmax) of BFI-751 with EU-Stelara and US-Stelara following a single 45 mg SC injection

    Measured: From Baseline to Day 85

  3. Bioequivalence - Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-tlast)

    Compare Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-tlast) of BFI-751 with EU-Stelara and US-Stelara following a single 45 mg SC injection

    Measured: From Baseline to Day 85

  4. Bioequivalence - Total AUC after extrapolation from time t to time infinity (AUC0-inf)

    Compare Total AUC after extrapolation from time t to time infinity (AUC0-inf) of BFI-751 with EU-Stelara and US-Stelara following a single 45 mg SC injection

    Measured: From Baseline to Day 85

  5. BioEquivalence - Elimination rate constant (Kel)

    Compare Elimination rate constant (Kel) of BFI-751 with EU-Stelara and US-Stelara following a single 45 mg SC injection

    Measured: From Baseline to Day 85

  6. Bioequivalence - Apparent terminal elimination half-life (t1/2)

    Compare Apparent terminal elimination half-life (t1/2) of BFI-751 with EU-Stelara and US-Stelara following a single 45 mg SC injection

    Measured: From Baseline to Day 85

  7. Bioequivalence - Volume of distribution (Vz)

    Compare Volume of distribution (Vz) of BFI-751 with EU-Stelara and US-Stelara following a single 45 mg SC injection

    Measured: From Baseline to Day 85

  8. Bioequivalence - Apparent clearance (CL)

    Compare Apparent clearance (CL) of BFI-751 with EU-Stelara and US-Stelara following a single 45 mg SC injection

    Measured: From Baseline to Day 85

Secondary outcomes (31)

  1. Safety and tolerability - Incidence, type and severity of Adverse Events

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Incidence, type and severity of Adverse Events

    Measured: From Baseline to Day 85

  2. Safety and tolerability - Changes from baseline in clinical laboratory results (haematology, serum chemistry, coagulation, and urinalysis)

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Changes from baseline in clinical laboratory results (haematology, serum chemistry, coagulation, and urinalysis)

    Measured: From Baseline to Day 85

  3. Changes from baseline in vital signs parameter - systolic and diastolic blood pressure in mmHg

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Changes from baseline in vital signs parameter - systolic and diastolic blood pressure in mmHg

    Measured: From Baseline to Day 85

  4. Changes from baseline in vital signs parameter - heart rate in beats per minute

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Changes from baseline in vital signs parameter - heart rate in beats per minute

    Measured: From Baseline to Day 85

  5. Changes from baseline in vital signs parameter - respiratory rate in breaths per minute

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Changes from baseline in vital signs parameter - respiratory rate in breaths per minute

    Measured: From Baseline to Day 85

  6. Changes from baseline in vital signs parameter - body temperature in degrees Celsius

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Changes from baseline in vital signs parameter - respiratory rate in breaths per minute

    Measured: From Baseline to Day 85

  7. Changes from baseline in physical examination findings - height in centimeters

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Changes from baseline in physical examination findings - height in centimeters. Weight and height will be combined to report BMI in kg/m^2.

    Measured: From Baseline to Day 85

  8. Changes from baseline in physical examination findings - weight in kilograms

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Changes from baseline in physical examination findings - weight in centimeters. Weight and height will be combined to report BMI in kg/m^2.

    Measured: From Baseline to Day 85

  9. Changes from baseline in triplicate 12-lead electrocardiograms (ECG) Ventricular HR

    Measured by assessment of Ventricular HR as normal, not having a clinically significant abnormality or having a clinically significant abnormality

    Measured: From Baseline to Day 85

  10. Changes from baseline in triplicate 12-lead electrocardiograms (ECG) PR Interval

    Measured by assessment of PR interval as normal, not having a clinically significant abnormality or having a clinically significant abnormality

    Measured: From Baseline to Day 85

  11. Changes from baseline in triplicate 12-lead electrocardiograms (ECG) RR interval

    Measured by assessment of RR interval as normal, not having a clinically significant abnormality or having a clinically significant abnormality

    Measured: From Baseline to Day 85

  12. Changes from baseline in triplicate 12-lead electrocardiograms (ECG) QRS duration

    Measured by assessment of QRS duration as normal, not having a clinically significant abnormality or having a clinically significant abnormality

    Measured: From Baseline to Day 85

  13. Changes from baseline in triplicate 12-lead electrocardiograms (ECG) QT interval

    Measured by assessment of QT interval as normal, not having a clinically significant abnormality or having a clinically significant abnormality

    Measured: From Baseline to Day 85

  14. Changes from baseline in triplicate 12-lead electrocardiograms (ECG) QTcF

    Measured by assessment of QTcF as normal, not having a clinically significant abnormality or having a clinically significant abnormality

    Measured: From Baseline to Day 85

  15. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: general appearance

    Measured: From Baseline to Day 85

  16. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: head

    Measured: From Baseline to Day 85

  17. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: ears

    Measured: From Baseline to Day 85

  18. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: eyes

    Measured: From Baseline to Day 85

  19. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: nose and throat

    Measured: From Baseline to Day 85

  20. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: neck (including thyroid and lymph nodes)

    Measured: From Baseline to Day 85

  21. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: respiratory

    Measured: From Baseline to Day 85

  22. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: cardiovascular

    Measured: From Baseline to Day 85

  23. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: gastrointestinal

    Measured: From Baseline to Day 85

  24. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: renal

    Measured: From Baseline to Day 85

  25. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: neurological condition

    Measured: From Baseline to Day 85

  26. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: musculoskeletal system

    Measured: From Baseline to Day 85

  27. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: skin

    Measured: From Baseline to Day 85

  28. Occurence of any clinical significant (CS) physical examination findings

    Measured by assessment of the following system: any other focused assessments suggested by the presence of specific symptoms.

    Measured: From Baseline to Day 85

  29. Safety and Tolerability - Incidence, type and severity of injection site reactions.

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Incidence, type and severity of injection site reactions.

    Measured: From Baseline to Day 85

  30. Immunogenicity - incidence of antidrug antibody (ADA)

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Incidence of antidrug antibody (ADA) and/or neutralising antibody (nAb) against 751-BFI, US- and EU-STELARA®, including titres for ADA.

    Measured: From Baseline to Day 85

  31. Immunogenicity - incidence of neutralising antibody (nAb)

    The secondary objective of the study is to investigate the safety, tolerability and immunogenicity of BFI-751, EU-Stelara and US-Stelara including Incidence of neutralising antibody (nAb) against 751-BFI, US- and EU-STELARA®.

    Measured: From Baseline to Day 85

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Apr 2021
  2. Study start1 Apr 2021
  3. Primary completion8 Dec 2021
  4. Study completion8 Dec 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double blinded, randomized, parallel group
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
216 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04843631
Sponsor's protocol ID
BFTA-AU-001
Status last verified
Mar 2022
First submitted
23 Mar 2021
Last updated
25 Mar 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Hausfeld JN, Challand R, McLendon K, Macapagal N, Bruce-Staskal P, Fiaschetti C, Sampey DB. Pharmacokinetic Profiles of a Proposed Biosimilar Ustekinumab (BFI-751): Results From a Randomized Phase 1 Trial. Clin Pharmacol Drug Dev. 2023 Oct;12(10):1001-1012. doi: 10.1002/cpdd.1305. Epub 2023 Jul 22.

    PubMed 37483071

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing BFI-751, EU-STELARA® and US-STELARA® in people with Psoriasis, run by BioFactura Australia Pty Ltd. at 3 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 20 inclusion and 42 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Australia, New Zealand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bioequivalence- Cmax (time frame: From Baseline to Day 85). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04843631, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2022.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in